tbuckley/cabot-search huggingface dataset:
Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises
Authors: A. J. Doorey
Journal: JAMA (1992)

<h3>Objective.</h3> —To assess the use of thrombolytic therapy for acute myocardial infarction, evaluating whether inclusion and exclusion criteria should be altered as well as the public health implications of any such alterations. <h3>Data Sources.</h3> —Data obtained were from English-language articles on the use of thrombolytic therapy in acute myocardial infarction. Articles that reported on inclusion and exclusion criteria as well as specific complications of this therapy were specifically sought. The review included articles under the terms<i>thrombolytic therapy and acute myocardial infarction</i>in the National Library of Medicine's MEDLINE database. <h3>Study Selection.</h3> —Studies selected for detailed review were those reporting specifics about inclusion and exclusion criteria and efficacy. Data extraction guidelines for assessing data quality included study size, patient population, detail of patient information acquired, and consecutive patient enrollment. <h3>Data Synthesis.</h3> —Thrombolytic therapy can provide substantial decrements of morbidity and mortality of acute myocardial infarction in the subset of patients who receive this therapy, but is underused in the United States. Advanced age per se should not be an exclusion criterion. Improvements can be made in electrocardiographic diagnosis of acute myocardial infarction. Many of the clinical conditions initially excluded from thrombolytic consideration, such as hypertension or having received cardiopulmonary resuscitation, are only relative contraindications. The benefit/risk ratio in treatment of these patients is often acceptable. Several well-documented points of delay from onset of symptoms to treatment can be minimized, and accelerated therapy can result in a reduction in mortality rates. <h3>Conclusion.</h3> —Significant public health benefits will result from greater use of thrombolytic therapy in acute myocardial infarction. (<i>JAMA</i>. 1992;268:3108-3114)
Uncomplicated myocardial infarction. Current physician practice in patient management
Authors: N. K. Wenger
Journal: JAMA (1973)

A questionnaire on management of uncomplicated acute myocardial infarction patients was mailed to 1,200 general practitioners, 1,200 internists, and 1,200 cardiologists. The 69% who responded managed approximately 70,000 patients with acute myocardial infarction in 1970. General practitioners saw three-fifths of these patients. Of acute myocardial infarction patients, 45% were considered to have uncomplicated infarction. Most responses were similar for general practitioners, internists, and cardiologists, who routinely hospitalized 95% of uncomplicated acute myocardial infarction patients for a 21-day hospital stay. Of physicians, 97% restricted smoking, 77% restricted calories, and 71% used anticoagulants. Of patients under age 65, 87% returned to work two to four months after uncomplicated myocardial infarction.
Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)
Authors: M. A. Henderson, B. Burmeister, J. F. Thompson, J. Di Iulio, R. Fisher, A. Hong, R. Scolyer, K. Shannon, H. Hoesktra, J. Ainslie
Journal: Journal of Clinical Oncology (2009)

LBA9084 Background: Adjuvant radiotherapy (RT) is an option for patients with isolated regional recurrence of melanoma considered to be at high risk of further regional recurrence after lymphadenectomy. This is the first completed study to assess the effects of RT on regional recurrence, survival, morbidity and quality of life (QOL) in these patients. Methods: Multicenter randomized study of patients with isolated regional recurrence at increased risk (&gt;25%) of regional recurrence. Eligibile patients included ≥1 parotid, ≥ 2 cervical or axillary or ≥ 3 groin nodes or extra nodal spread of tumor or maximum metastatic node diameter ≥3cm in neck or axilla or ≥4cm in the groin. Patients were randomized to observation or regional nodal basin RT (48Gy in 20 fractions) after lymphadenectomy. Regional recurrence was the primary end point and morbidity, QOL, patterns of relapse, disease free and overall survival were secondary end points. The target sample size was 220 patients, which would enable a difference in 3 year regional relapse (cumulative incidence) rates of 30% versus 15% to be detected with a power of 80% (using a two sided logrank test at the 5% level of significance). Results: 250 pts were randomized from 16 centers from March 2002 to September 2007. There were 123 in the RT group and 127 in OBS group. 2 pts withdrew consent and 31 were excluded from analysis of the main objective following an independent blinded review of eligibility compliance by two reviewers. 227 pts were available for analysis of the main objective (109 RT, 108 OBS). Median follow-up was 27 mo. There was a statistically significant improvement in lymph node field control with radiotherapy, 20 RT pts and 34 OBS pts relapsed (HR 1.77 1.02–3.08 p=0.041). Median survival times were 2.6 years (RT) and 3.9 years (OBS) p=0.14. Conclusions: Adjuvant RT improved regional control in melanoma patients at high risk of regional relapse after lymphadenectomy. An effect on survival was not demonstrated. No significant financial relationships to disclose.
Pathologische Histologie. Ein Unterrichtskurs für Studierende und Aerzte.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Statin Therapy and Cognitive Deficits Associated With Neurofibromatosis Type 1—Reply
Authors: Ype Elgersma
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Preventive Medicine
Authors: William H. Foege
Journal: JAMA (1989)

The remarkable evolution of preventive medicine to include problems such as violence, environmental contamination, and chronic diseases continues. Simultaneously, the science base has improved, leading to viral fingerprinting in poliomyelitis eradication programs, computer assessment of individual health risks, and chemicaldetection abilities exceeding interpretive abilities. Some developments warrant special note. A detailed evaluation of the future of public health was issued by the Institute of Medicine.<sup>1</sup>The Institute of Medicine committee concluded that toxic exposures, acquired immunodeficiency syndrome, and addiction, together with such traditional problems as sanitation, infectious diseases, and nutrition, require strengthening US public health abilities. The committee reports that "an impossible responsibility has been placed on America's public health agencies" and that defects in organization, funding, and strategy must be addressed. The committee provided a contemporary mission statement of public health as carrying out society's interest in assuring conditions in which people can be healthy. Governmental health agencies
Effects of Long-Term Administration of Tolbutamide in Normal, Subdiabetic, and Diabetic Rats
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antistenosis approaches revisited, or rating the artery openers anew
Authors: M. F. Goldsmith
Journal: JAMA (1991)

CLEARING OUT the recurrent underbrush of fatty debris in the arterial jungle is the goal of cardiologic explorers today. Despite the nearly routine restoration of blood flow through once-clogged coronary vessels that "balloon angioplasty" makes possible, restenosis continues to be a problem. Following attack by blasting, cutting, scraping, melting, and other efforts, the plaque comes back. At the 64th annual Scientific Sessions of the American Heart Association (AHA), held in Anaheim, Calif, many presentations dealt with the safety and efficacy of alternative devices designed during the past few years to remove fatty deposits or prop open arterial walls after percutaneous transluminal coronary angioplasty (PTCA). Sometimes the new methods are tried first. In either case, success has not been great. <h3>Experimental Now, Clinical in '92?</h3> The major devices include specialized balloon and laser catheters, mechanical atherectomy or ablation devices, and metallic and bioabsorbable stents. With one exception (the Atherocath, which has
The Heart Rhythms.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combined internships between community hospitals
Authors: G. L. Haidak
Journal: JAMA (1968)

For the past seven years the physicians of Pittsfield, Mass, have been engaged in an experiment in graduate medical education. This report states the purpose of the project, describes the initial phases, preliminary results, and discusses the interrelationships between a community hospital and a university medical center. Medical educators agree that the highest quality of education, with few exceptions, is found in the university environment. In 1966, university hospitals accommodated only one half the total number of house officers; the other half were located in nonuniversity hospitals. Since university hospitals cannot soon cope with this problem, an urgent challenge emerges: Community hospital programs, of comparable caliber to the university medical center, must be developed.<sup>1</sup> The Pittsfield Affiliated Hospitals Education Program was devised to produce an educational environment by simulating the university medical center. The Council on Medical Education has been continuously consulted about the objectives and the progress of
Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures
Authors: S. S. Dikmen
Journal: JAMA (1991)

In order to determine potential negative neurobehavioral effects of phenytoin given to prevent the development of posttraumatic seizures, 244 subjects were randomized to phenytoin or placebo. They received neurobehavioral assessments at 1 and 12 months postinjury while receiving their assigned drug and at 24 months while receiving no drugs. In the severely injured, phenytoin significantly impaired performance at 1 month. No significant differences were found as a function of phenytoin in the moderately injured patients at 1 month or in either severity group at 1 year. Patients who stopped receiving phenytoin according to protocol between 1 and 2 years improved more than corresponding placebo cases on several measures. We conclude that phenytoin has negative cognitive effects. This, combined with lack of evidence for its effectiveness in preventing posttraumatic seizures beyond the first week, raises questions regarding its use for long-term prophylaxis. Our findings do not negate phenytoin's proven efficacy in controlling established seizures nor do they indicate that its cognitive effects are worse than other anticonvulsant drugs. (<i>JAMA</i>. 1991;265:1271-1277)
Community-academic health center partnerships for underserved minority populations. One solution to a national crisis
Authors: D. M. Levine
Journal: JAMA (1994)

NOWHERE are the national issues concerning health care more magnified than in underserved minority populations that suffer significantly higher rates of premature morbidity, disability, and mortality than the rest of the US population. It is noteworthy that the majority of the causes of this disparity, such as smoking, hypertension, hyperlipidemia, substance abuse, violence, and various cancers, are either preventable or treatable and controllable. Whatever emerges from national health care system reform, it will be insufficient if we do not make significant progress in decreasing the gap in the health status of underserved, minority populations. Communities of underserved minority populations are frequently found in the same locale as are academic health centers. In fact, of the 126 academic health centers, approximately 75% are found in circumstances of this nature.<sup>1</sup>The mission of such centers is to gain new knowledge through research to enhance the health of the public, as well
Re: Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.023
Authors: Glen Denmer Santok, Koon Ho Rha
Journal: European Urology (2016)
Initiation of Acute Graft-Versus-Host Disease By Angiogenesis
Authors: Katarina Riesner, Yu Shi, Angela Jacobi, Martin Kraeter, Martina Kalupa, Aleixandria McGearey, Sarah Mertlitz, Steffen Cordes, Jens-Florian Schrezenmeier, Joerg Mengwasser, Sabine Westphal, Daniel Perez-Hernandez, Clemens Schmitt, Gunnar Dittmar, Jochen Guck, Olaf Penack
Journal: Blood (2016)
Sunday Best
Authors: Brittany Sprigg
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mortality From Congestive Heart Failure— United States, 1980-1990
Journal: JAMA (1994)

In the United States, congestive heart failure (CHF) was the underlying cause of death for approximately 38,000 persons in 1990; of those deaths, approximately 92% were among persons aged > or = 65 years. CHF, a clinical syndrome defined as a chronic inadequate contraction of the heart muscle resulting in insufficient cardiac output, is a manifestation of one or more underlying conditions, including systemic or pulmonary hypertension or a history of other heart diseases (e.g., myocardial infarction, atherosclerosis, cardiomyopathy, congenital heart disease, or rheumatic fever). The long-term prognosis of CHF depends on the underlying condition and the response of that condition to treatment. Despite declines in death rates for ischemic heart disease and cerebrovascular disease, improvements in detection and treatment of hypertension, and considerable advances in the diagnosis and management of CHF, mortality from CHF has increased since 1980. This report summarizes trends in CHF mortality in the United States during 1980-1990 and presents state-specific mortality data for 1990 (the most recent year for which such data are available).
Contents, Vol. 35, No. 4, 1981
Authors: J.H. van Birgelen, J.A. Hartzuiker, J. van Londen, Peter E. Sifneos, Astrid N. Heiberg, Fred H. Frankel, Edmond Gilliéron, Miguel A. Leibovich, Roland Pierloot
Journal: Psychotherapy and Psychosomatics (1981)
Reply
Authors: R Eliakim, D Rachmilewitz
Journal: Gut (1994)

EDITOR,-We are glad that Dr Jolobe agreed with the importance of considering coeliac disease in patients with iron deficiency anaemia, even when symptomatology is atypical.The precaution of taking endoscopic biopsy specimens prevents oversight of the diagnosis.We also note his comment on the abnormal appearance of duodenal folds in coeliac disease.We indeed routinely comment on such abnormalities having previously pub- lished evidence' supporting the data of Brocchi et al.'
BUCHAREST
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sterol O-Acyltransferase 1 (SOAT1, ACAT) Is a Novel Target of Steroidogenic Factor-1 (SF-1, NR5A1, Ad4BP) in the Human Adrenal
Authors: Bruno Ferraz-de-Souza, Rebecca E. Hudson-Davies, Lin Lin, Rahul Parnaik, Mike Hubank, Mehul T. Dattani, John C. Achermann
Journal: Endocrine Reviews (2011)

Steroidogenic factor-1 (SF-1, NR5A1, Ad4BP) is a master regulator of adrenal development and steroidogenesis. Defects in several known targets of SF-1 can cause adrenal disorders in humans. We aimed to identify novel targets of SF-1 in the human adrenal. These factors could be important regulators of adrenal development and steroidogenesis and potential candidates for adrenal dysfunction. A gene discovery strategy was developed based on bidirectional manipulation of SF-1. Overexpression or knockdown of SF-1 in NCI-H295R human adrenocortical cells was used to identify a subset of positively-regulated SF-1 targets. This approach identified well-established SF-1 target genes (STAR, CYP11A) and several novel genes (VSNL1, ZIM2, PEG3, SOAT1, and MTSS1). Given its role in cholesterol metabolism, sterol O-acyltransferase 1 (SOAT1, previously referred to as acyl-Coenzyme A:cholesterol acyltransferase 1, ACAT) was studied further and found to be expressed in the developing human fetal adrenal cortex. We hypothesized that impaired SOAT1 activity could result in adrenal insufficiency through reduced cholesteryl ester reserves or through toxic destruction of the adrenal cells during development. Therefore, mutational analysis of SOAT1 in a cohort of 43 patients with unexplained adrenal insufficiency was performed but failed to reveal significant coding sequence changes. Our reverse discovery approach led to the identification of novel SF-1 targets and defined SOAT1 as an important factor in human adrenal steroidogenesis. SF-1–dependent up-regulation of SOAT1 may be important for maintaining readily-releasable cholesterol reserves needed for active steroidogenesis and during episodes of recurrent stress.